Search News Archives
Follow us on
Conferences | Events

Media Partners

 

BioFocus enters collaboration with Michael J. Fox Foundation

BiofocusBioFocus announced today that it has signed a collaboration agreement with The Michael J. Fox Foundation for Parkinson's Research, a not-for-profit organization focused on developing therapies for Parkinson's disease.  Under the agreement, BioFocus will perform fragment-based screening, assay development and hit-finding programs, to identify compounds that have the basis for a novel Parkinson's disease diagnostic test.  

"We are delighted to have the opportunity to support The Michael J. Fox Foundation in its development of improved therapies for those living with Parkinson's," said Dr Kate Hilyard, VP Biological Sciences.  "The collaboration will utilize BioFocus' biology platform that delivers drug discovery solutions through its experienced teams and state-of-the-art technologies".

About The Michael J. Fox Foundation for Parkinson's Research 

As the world's largest private funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding over $240 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.  

About BioFocus

BioFocus delivers drug discovery solutions through a comprehensive platform run by dedicated teams with a track record in gene-to-clinical candidate discovery.  BioFocus' offering includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry and ADME/PK services, supported by unique chemogenomic and informatics tools.  As a service division of Galapagos, BioFocus has over 210 employees with research facilities in three countries.  More information at: www.biofocus.com.

BioFocus® and SilenceSelect® are trademarks of Galapagos NV and/or its affiliates © Copyright 2011 Galapagos NV.


If you have not logged into the website then please enter your details below.



 


Popular this Month

 

Win a PIPETBOY from the new Integra summer collection!

 

Great Savings off Selected GC Columns

 

CytoSMART raises 5.2 million Euros for further product innovation and growth

 

High Volume Sample Storage in Space Efficient 96-Well Format

 

Cherwell Publishes Guide on Sterility Testing

 

Effective Removal of DMSO from Stored Samples

 

ATL Webcast: A Practical Guide to Selecting the Right LIMS

 

Genetic study reveals how gut bacteria work to keep us healthy

 

Lonza Establishes Custom Cell Biology Services to Offer Unique Manufacturing and Testing Capabilities

 

Thermo Fisher Scientific Opens Food Safety Customer Solution Center in India

 

 


 

 


 

Can't find what you are looking for?

Search by company or by product


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd